Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Femasys Inc (FEMY)

Femasys Inc (FEMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,527
  • Shares Outstanding, K 58,480
  • Annual Sales, $ 1,630 K
  • Annual Income, $ -18,820 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta -2.59
  • Price/Sales 26.13
  • Price/Cash Flow N/A
  • Price/Book 7.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.72
  • Most Recent Earnings $-0.10 on 11/14/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5403 +12.47%
on 12/29/25
0.9900 -38.62%
on 12/01/25
-0.4023 (-39.83%)
since 11/28/25
3-Month
0.3420 +77.69%
on 09/30/25
1.1100 -45.25%
on 11/11/25
+0.2557 (+72.64%)
since 09/29/25
52-Week
0.3067 +98.14%
on 08/26/25
1.8000 -66.24%
on 02/21/25
-0.5223 (-46.22%)
since 12/27/24

Most Recent Stories

More News
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE)...

FEMY : 0.6004 (-15.45%)
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company’s...

PMCB : 0.7065 (-0.51%)
FEMY : 0.6004 (-15.45%)
Femasys Announces Third Quarter Financial Results for 2025

– FDA Approval to Advance Final FemBloc ® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway...

FEMY : 0.6004 (-15.45%)
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE)...

FEMY : 0.6004 (-15.45%)
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured...

FEMY : 0.6004 (-15.45%)
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe

--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...

FEMY : 0.6004 (-15.45%)
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.6004 (-15.45%)
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership

ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.6004 (-15.45%)
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed

ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.6004 (-15.45%)
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 0.6004 (-15.45%)

Business Summary

Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA.

See More

Key Turning Points

3rd Resistance Point 0.7751
2nd Resistance Point 0.7620
1st Resistance Point 0.7361
Last Price 0.6004
1st Support Level 0.6971
2nd Support Level 0.6840
3rd Support Level 0.6581

See More

52-Week High 1.8000
Fibonacci 61.8% 1.2296
Fibonacci 50% 1.0533
Fibonacci 38.2% 0.8771
Last Price 0.6004
52-Week Low 0.3067

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar